New and Recurrent Colorectal Cancers After Resection: a Systematic Review and Meta-analysis of Endoscopic Surveillance Studies by Fuccio, Lorenzo et al.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
New and Recurrent Colorectal Cancers After Resection: a Systematic Review 
and Meta-analysis of Endoscopic Surveillance Studies 
Lorenzo Fuccio, MD,1 Douglas Rex, MD,2 Thierry Ponchon, MD,3 Leonardo Frazzoni, MD,1 Mário Dinis-
Ribeiro, MD,4 Pradeep Bhandari,5 MD, Evelien Dekker, MD,6 Maria Pellisè,7 Loredana Correale, PhD,1
Jeanin van Hooft,6 MD, Rodrigo Jover, MD,8 Diogo Libanio, MD,4 Franco Radaelli, MD,9 Sergio Alfieri, 
MD10 Franco Bazzoli, MD,1 Carlo Senore, PhD11 Jaroslaw Regula, MD12 Thomas Seufferlein, MD13 Thomas 
Rösch, MD14 Prateek Sharma, MD15 Alessandro Repici,16 MD, and Cesare Hassan, MD.16
1Department of Medical and Surgical Sciences, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; 2Division of 
Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, Indiana; 3Gastroenterology and Endoscopy, Edouard Herriot 
Hospital, Lyon, France; 4CIDES/CINTESIS, Faculty of Medicine, University of Porto, Porto, Portugal; 5Queen Alexandra Hospital, Cosham, 
Portsmouth, UK; 6Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The 
Netherlands; 7Gastroenterology Department, Endoscopy Unit, ICMDiM, Hospital Clinic, CIBEREHD, IDIBAPS, University of Barcelona, Catalonia, 
Spain; 8Service of Digestive Medicine, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain; 
9Department of Gastroenterology; Valduce hospital, Como, Italy; 10Digestive Surgery Department, Catholic University of Sacred Heart, Rome, 
Italy;11Azienda Ospedaliero Universitaria Cittá della Salute e della Scienza Centro per l'Epidemiologia e la Prevenzione Oncologica in Piemonte, 
Turin, Italy;12The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; 13Klinik für Innere Medizin, 
Universitätsklinikum Ulm, Ulm, Germany.  14Department of Interdisciplinary Endoscopy, University Hospital Hamburg-Eppendorf, Hamburg, 
Germany; 15Division of Gastroenterology & Hepatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, 
Missouri, USA; 16Digestive Endoscopy Unit, Division of Gastroenterology, Humanitas Research and University Hospital, Rozzano (MI), Italy.
Abbreviations used: CI, confidence intervals; CRC, Colorectal Cancer; NA, Not Available.
Financial support: None; Grant support: None; Potential competing interests: None.
Specific author contributions: Concept and design: Fuccio L, Rex D, Hassan C; analysis and 
interpretation of the data: Fuccio L, Rex D, Correale L, Frazzoni L, Hassan C; drafting of the 
article: Fuccio L, Rex D, Correale L, Hassan C; statistical expertise: Correale L; collection and 
assembly of data: Fuccio L, Frazzoni L, Hassan C; critical revision of the article for important 
intellectual content: all the Authors; final approval of the article: all the Authors. 
Correspondence to 
Prof. Lorenzo Fuccio, MD, 
Gastroenterology Unit,
Department of Medical and Surgical Sciences (DIMEC), 
S.Orsola-Malpighi University Hospital,
Bologna, 40138, Italy
Email: lorenzofuccio@gmail.com
Phone/FAX numeber: +39-51-2143338
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Fuccio, L., Rex, D., Ponchon, T., Frazzoni, L., Dinis-Ribeiro, M., Bhandari, P., … Hassan, C. (2018). New and Recurrent Colorectal 
Cancers After Resection: a Systematic Review and Meta-analysis of Endoscopic Surveillance Studies. Gastroenterology. 
https://doi.org/10.1053/j.gastro.2018.12.006
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
ABSTRACT  
Background & Aims: Outcomes of endoscopic surveillance following surgery for colorectal 
cancer (CRC) vary with the incidence and timing of CRC detection, at anastomoses or non- 
anastomoses in the colorectum. We performed a systematic review and meta-analysis to evaluate 
the incidence of CRCs identified during surveillance colonoscopies of patients who have already 
undergone surgery for this cancer.  
 
Methods: We searched PubMed, EMBASE, SCOPUS, and the Cochrane Central Register of 
Clinical Trials through January 1, 2018 to identify studies investigating rates of CRCs at 
anastomoses or other locations in the colorectum after curative surgery for primary CRC. We 
collected data from published randomized controlled, prospective, and retrospective cohort studies. 
Data were analyzed by multivariate meta-analytic models. 
 
Results: From 2373 citations, we selected 27 studies with data on 15,803 index CRCs for analysis 
(89% of patients with stage 1–3 CRC). Overall, 296 CRCs at non-anastomotic locations were 
reported over time periods of more than 16 years (cumulative incidence, 2.2% of CRCs; 95% CI, 
1.8%–2.9%). The risk of CRC at a non-anastomotic location was significantly reduced more than 
36 months after resection compared with before this timepoint (odds ratio for non-anastomotic 
CRCs at 36–48 months vs 6–12 months after surgery, 0.61; 95% CI, 0.37–0.98; P=.031); 53.7% of 
all non-anastomotic CRCs were detected within 36 months of surgery. One hundred fifty-eight 
CRCs were detected at anastomoses (cumulative incidence of 2.7%; 95% CI, 1.9%–3.9%). The risk 
of CRCs at anastomoses was significantly lower 24 months after resection than before (odds ratio 
for CRCs at anastomoses at 25–36 months after surgery vs 6–12 months, 0.56; 95% CI, 0.32–0.98; 
P=.036); 90.8% of all CRCs at anastomoses were detected within 36 months of surgery. 
 
Conclusions: After surgery for CRC, the highest risk of CRCs at anastomoses and at other 
locations in the colorectum is highest during 36 months after surgery—risk decreases thereafter. 
Patients who have undergone CRC resection should be evaluated by colonoscopy more closely 
during this time period. Longer intervals may be considered thereafter.  
 
KEY WORDS:  colon cancer; recurrence; endoscopy; early detection 
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INTRODUCTION 
 Worldwide, over 1.8 million new colorectal cancer (CRC) cases are estimated to occur in 
2018, ranking third in terms of incidence and accounting for about 1 in 10 of all cancer cases 1. 
Despite a wide variation of its incidence by world region, a steady increase in incidence has been 
observed, in particular a generational change and a rise in transitioning countries. Indeed, CRC 
incidence may be considered a surrogate marker of socioeconomic development 1.  
 Patients with a history of CRC are at increased risk of developing metachronous colorectal 
lesions, therefore post-CRC surgery patients are generally recommended to adhere to colonoscopy-
based surveillance protocols 2. The main goals of surveillance colonoscopy are to diagnose cancers 
at anastomotic and non-anastomotic location at a curable stage, and to prevent the development of 
new cancer by detecting and removing precancerous lesions. Cancer at anastomotic location 
generally represents recurrent cancer while cancer at non-anastomotic location may represent, 
according to the timing of previous colonoscopy and site of detection, new onset cancer, missed or 
incompletely resected lesions 3. Current guidelines recommend performing surveillance 
colonoscopy 1 year after surgery; the interval to the next colonoscopy should be 3 years and then 5 
years; thereafter, colonoscopies should occur at 5-year intervals.2. This protocol was based on a 
systematic review of the literature performed by a panel of experts, however a formal systematic 
review with meta-analysis on this issue has never been performed.   
 Thus, aim of the present systematic review was to evaluate the incidence of cancer at 
anastomotic and non-anastomotic location diagnosed during surveillance colonoscopy in order to 
help decision-makers on the most appropriate intervals of colonoscopy-based surveillance in 
patients with a history of CRC. 
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METHODS 
We followed the PRISMA guideline and checklist for reporting systematic reviews and meta-
analyses4.  
 
Data Sources and Searches 
 We performed a comprehensive literature search by consulting PubMed, EMBASE, 
SCOPUS, and the Cochrane Central Register of Clinical Trials (up to Jan 1st, 2018) to identify full-
text studies, published in English, investigating the rate of CRCs at anastomotic and non-
anastomotic location occurring after curative surgery for primary CRC. ClinicalTrials.gov was 
assessed for ongoing or recently completed trials, and PROSPERO for ongoing or recently 
completed systematic reviews. Electronic searches were integrated by manual searches of 
references of included studies. 
 We used the following medical subject headings (MeSH) and keywords to include studies: 
("colon"[MeSH Terms] OR "colon"[All Fields] OR "rectum"[MeSH Terms] OR "rectum"[All 
Fields] OR "colorectal"[All Fields]) AND ("General Surgery/surgery”[MeSH Terms] OR 
"resection"[All Fields]) OR “colectomy”[All Fields] AND ("Colonoscopy”[All Fields] OR 
"Colonoscopy"[Mesh] OR "Endoscopy"[Mesh]) AND ("Surveillance”[All Fields] OR "Follow 
up”[All Fields]) AND English[lang]. 
 
Study Selection 
We ran a literature search to identify all relevant randomized controlled trials (RCTs), and 
prospective or retrospective cohort studies investigating the occurrence of CRC at anastomotic 
and/or non-anastomotic location after curative surgery, published since 1985. In order to be 
included in our search, studies had to use complete colonoscopy as the surveillance procedure, to 
specify the colonoscopy-based surveillance protocol and report the timing of diagnosis of cancer at 
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non-anastomotic (NA-CRC) or anastomotic (A-CRC) location. Studies conducted in specific 
setting, i.e. inflammatory bowel disease, and hereditary CRC syndromes (e.g. Lynch syndrome or 
Familial Adenomatous Polyposis syndromes) were excluded. Other exclusion criteria were review 
articles, abstracts, case reports, editorials, and corresponding letters not reporting original results. 
 
Data Extraction and Quality Assessment  
 Three independent reviewers (LF, LFr, CH) evaluated the eligibility of the publications for 
selection, resolving any disagreement by consensus assessment. We registered the reasons for 
excluding studies. The authors were not blinded to the journal titles nor to the study authors or 
institutions. 
 The following data were extracted for each study: publication status, publication year, 
enrolment period, study design and location, number of centers involved, study population, patient 
characteristics (e.g. site of primary tumor, mean age and gender), follow-up period and protocol 
(i.e., according to US Multi-Society Task force on CRC recommendations3, namely 1-, 3- and 5-
year protocol or not following US recommendations), number, site, stage and timing of CRCs at 
anastomotic and non-anastomotic location found during surveillance. We used a modified 
Newcastle-Ottawa scale to assess the risk of bias in included studies 5. 
 
Outcomes assessment  
The primary outcomes of this study were rates and timing of CRCs at anastomotic and non-
anastomotic location. Outcomes were assessed at progressive time-intervals of 12 months (i.e. time-
point rates, ranging from 6-12 months to 180 months) after primary resection. For each included 
study, time-interval rates were calculated as the number of A/NA-CRCs occurred in a given time 
interval, divided by the total number of patients with CRC. All the analyses performed assumed no 
‘drop out’, that is, that no participants were censored. Only very few studies provided exhaustive 
information about drop-out rates. For consistency, drop out was ignored in our analyses.  Since 
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some studies did not report data on all time-intervals, the number of time-interval rates differed 
between studies. Hence, there were missing data on some of the 12-month time-intervals. For 
recurrence, we also performed a subgroup analysis between colon vs. rectal localization of the index 
tumor, for those studies providing this information. 
 To assess the robustness of our results (to the assumption that all patients included in the 
follow-up spanned the entire follow-up period), subgroup and sensitivity analyses were carried out 
(see supplementary appendix for details). We also assessed the cumulative proportion of all A- or 
NA-CRCs over times. The cumulative proportion of A- or NA-CRCs at a given time was computed 
as the number of A- or NA-CRCs observed at all time-intervals preceding that time, divided by the 
number of all A- or NA-CRCs discovered during the entire follow-up period.  
Variables potentially influencing the occurrence of A- and/or NA-CRCs were also 
investigated. The a priori selected covariates were: demographic characteristics (i.e. mean age, 
male gender proportion), clinical features (i.e. primary CRC site, endoscopic surveillance protocol 
and timing) and study size. Secondary outcomes included the cumulative proportions of A- and 
NA-CRCs at different follow time intervals.  
 
Data Synthesis and Analysis. 
 In our meta-analyses, each study provided outcome values for several time-intervals and 
these values were inherently dependent. Effectively, true outcomes within a study might be more 
similar to each other than between-studies (correlated true outcomes). Therefore, the assumption of 
statistical independence, which underlines classical meta-analytic strategies, was violated. In cases 
where an effect size is reported at each one of multiple pre-determined time points, a multivariate 
meta-analysis via linear (mixed-effects) models can be used to estimate overall effect sizes at each 
time, while taking account of any correlation between effect sizes, both within and between studies 
6,7
. 
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All analyses were conducted in R version 3.3.2 8, with the package metafor 9. The rma.mv function 
was used to fit the multivariate random effects model. In this model, the time was entered as a 
predictor of a second CRC and the study was included as a random factor to deal with non-
independent samplings from a single study and to consider variation in findings among studies. In 
details, the model allowed each study to have a different effect at each time point. The model 
requires specifications of the covariance structure for the correlation between with-study effects. 
Therefore, we compared models where this correlation was accounted for in different alternatives, 
including 1) a random-effects model accounting for this correlation using the compound symmetry 
structure (i.e., correlations are assumed to be the same for each set of time points, regardless of the 
time lag between the time points); 2) a correlated random-effect model that accounts for within-
study serial correlation between effects using the autoregressive structure (i.e., the dependence 
between effect sizes become stronger as the lag between them gets smaller); 3) a random-effect 
model assuming complete independence between random-effects and residuals. The latter is 
equivalent to meta-analyzing the data at each time separately (independent random-effect meta-
analysis). The models were compared by likelihood-ratio tests and Akaike information criteria 
(AIC) (see Supplementary Appendix for details). Results from the best fitting model (i.e. AR = 
autoregressive structure) were reported here. Study-level covariates (e.g. year of publication, 
gender, study country) and interaction terms between variables and time were also included in the 
analyses as predictors or moderator of effects over time, to explain residual heterogeneity. These 
covariates were considered to have fixed-effects and, therefore, did not impact the specification of 
correlation. 
The above-mentioned methodology was also applied to assess the cumulative proportion of 
patients with A- and/or NA-CRCs at successive time intervals of 12 months. 
 Meta-analyses can be subject to publication bias. In order to check the presence of 
publication bias in our dataset, we tested correlations between the observed outcomes and the study 
sample size. We tested this by including the total sample size of the study as a covariate in the 
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multivariate regression model. Further, we performed a trim-and-fill procedure to determine the 
number of missing studies based on a pooled effect that adjusts for bias by imputing studies that 
make the funnel plot more symmetric 10. An estimate of the A-/NA-CRCs rate when including these 
potentially missing studies was reported. Since there are methodological difficulties in the use of 
trim-and-fill procedures in multivariate meta-analytic data, the trim-and-fill procedure was 
performed for each time-interval, separately.    
 
RESULTS 
Characteristics of the included studies 
Our search identified 2,373 publications, of which 27 studies were included in the analysis 
for a total of 15,589 patients, and 15,803 index CRCs (Supplementary Figure 1) 11–37. Baseline 
characteristics of the included studies are detailed in Tables 1-3. Overall, 14 (52%) studies were 
conducted in Europe, 7 (26%) in Asia, 4 (15%) in North America and 2 (7%) in Australia. The 
publication year ranged from 1986 to 2017; in detail, 12 (44%) studies were published before 2000, 
5 (19%) between 2000 and 2005, and 10 (37%) after 2005. Seventeen (63%) articles were 
retrospective, and 25 (93%) studies were conducted at a single center. Five studies19,27,29,35,37 
followed the 1-3-5-year surveillance protocol. Twenty-one studies11,12,14,16–18,20,22,23,25–27,29,31–37 
performed clearing colonoscopy in the peri-operative time period. Three studies 21,36,37 clearly stated 
that “high-quality” colonoscopy, i.e. scope introduction up to the caecum or ileo-colonic 
anastomosis with adequate bowel preparation was carried out, whilst all the other studies did not 
provide any information on this issue.  
Among included patients, mean age ranged from 54 to 71 years, whereas male gender 
proportion ranged from 46% to 69%. Seventeen studies for a total of 13,085 CRCs reported the 
stage of primary CRC, of which 3,016 (23%) were stage I, 4,805 (37%) stage II, 3,829 (29%) stage 
III, and 1,435 (11%) stage IV.  Fifteen studies reported the colon location of primary CRCs, for a 
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total of 3,664 cases of which 2,401 (65.5%) were located in the colon and 1,266 (34.5%) in the 
rectum.  The mean length of follow-up varied across the studies, ranging from 18 to 108 months. 
 
 
CRC at Non-Anastomotic Location 
Non-Anastomotic CRC rate at various time-intervals 
Twenty-seven studies with 15,589 patients provided data on NA-CRCs occurrence.  Overall, 
296 NA-CRCs were reported during a follow-up period of up to >16 years, corresponding to an 
overall cumulative incidence of 2.2% (95% CI: 1.8-2.9%). Tumor stage was available for 206 NA-
CRCs, of which 125 (61%) were stage I to II. Colon location was reported in 215 NA-CRCs, of 
which 95 (44%) were located proximally to the splenic flexure and 120 (56%) in the distal colon.  
Among the included studies, 202 estimates of NA-CRCs rate were reported in at least one of the 
specified time-intervals. Six studies reported data on NA-CRCs for all 16 time intervals 
13,16,19,24,27,36
. 
 The pattern of the results was the same across all the 3 investigated models (see details in 
the Supplemental Appendix): the odds of NA-CRCs at time points >36 months after resection 
were lower as compared with those at the first 36 months. Time interval rates from the best fitting 
model (AR structure)  are displayed in Figure 1. In details, NA-CRCs rate was 0.74% (95% 
CI:0.50-1.09%) at 6-12 months after resection and it did not decrease (0.63% 95% CI:0.47-0.90%; 
OR: 0.81; 95% CI: 0.53-1.26; P=0.349) at 13-24 months and at 25-36 months (0.69%; 95% 
CI:0.49-1.01%; OR, 0.94; 95% CI:0.62-1.46; P=0.778). Time-points >36 months provided 
significantly different estimates. At 37-48 months, a significant decrease in the NA-CRCs rate (as 
compared with 6-12 months rate) was observed, corresponding to an estimated rate of 0.45% (95% 
CI: 0.29-0.70%; OR: 0.61; 95% CI: 0.37-0.98; P=0.031). The incidence of NA-CRCs remained 
very low in the remaining intervals of follow-up (as compared with 6-12 months), corresponding to 
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0.34% (95% CI:0.24-0.58%; OR: 0.48; 95% CI:0.29-0.81; P=0.005) at 49-60 months, to 0.29% 
(95% CI:0.15-0.56% OR: 0.41; 95% CI:0.19-0.84; P=0.016) at 85-96 months, and to 0.28% (95% 
CI:0.14-0.57%; OR: 0.38; 95% CI:0.18-0.81; P=0.011) at 109-120 months. 
 Patients with a diagnosis of stage IV cancer were generally not included in the studies, 
unless oncological curative resection of metastases was achieved.  Only one study included a large 
group of Stage IV cases (25.6% of the entire study population) 36.  A sensitivity analysis excluding 
the study by le Clercq et al36 was carried out and the main findings did not substantially change: 
NA-CRCs occurred in 0.82% (95% CI:0.55-1.23%) between 6 and 12 months, 0.61% (95% 
CI:0.41-0.91%) between 12 and 24 months and in 0.72% (95%CI:4.8-1.1%) between 25-36 months. 
Differences were not significant. Over the longer time-intervals, rate of NA-CRCs decreased to 
0.51% (95%CI:0.32-0.81%) between 37 and 48 months (P=0.092) and to 0.41% (95%CI:0.26-
0.66%) between 49 and 60 months (P=0.012). 
 
Cumulative proportion of non-anastomotic CRCs on all non-anastomotic CRCs, at various time-
intervals. 
 Among the included studies, 53.7% (95% CI:41.3-65.7%) of all discovered NA-CRCs 
occurred within 36 months after resection, 70.4% (95% CI:60.0-79.7%) within 60 months, and 
89.0% (95% CI:82.1-93.5) within 120 months (Figure 2).  
 
Predictors of CRC rate at non-anastomotic location  
 Overall, the only variable significantly associated with NA-CRCs rate was the study size, so 
that larger studies were significantly associated with lower NA-CRCs rates (OR: 0.96; 95% CI: 
0.95-0.98; P<0.001) (see Supplemental Table 1). 
 
CRC at Anastomotic Location 
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Anastomotic CRC rate at various time-intervals  
 Among 25 studies for a total of 6,048 patients in which time-point data on CRCs at 
anastomotic location were given, 158 A-CRCs were reported during a follow-up period of up to 16 
years, corresponding to an overall incidence of 2.7% (95% CI: 1.9-3.9%). Of note, no A-CRC was 
reported for time intervals ≥ 60-72 months after surgical intervention. 
 On multivariate meta-analysis, the follow-up time interval was significantly associated with 
outcome (see Figure 3). The highest rate was at 6-12 months after resection, being 1.7% (95% CI: 
1.04-2.8%) and it did not differ significantly at 13-24 months (1.23%; 95% CI: 0.74-2.1%; 
P=0.219; OR: 0.72; 95% CI: 0.44-1.24; P=0.219). Time points >24 months provided significantly 
lower estimates compared to 6-12 months: at 25-36 months, the rate was 0.93% (95% CI: 0.53-
1.60%; P=0.036; OR: 0.56; 95% CI: 0.32-0.98; P=0.036) and further decreased to 0.30% (95% CI: 
0.14-0.64; P=0.006; OR: 0.18; 95% CI: 0.08-0.39; P=0.001) at 37-48 months. 
 
Cumulative proportion of anastomotic CRCs on all anastomotic CRCs, at various time-intervals 
 Among the included studies, 70.5% (95% CI:53.6-83.2%) of all discovered A-CRCs 
occurred within 24 months, 90.8% (95% CI:80.9-95.9%) within 36 months, 91.2% (95% CI: 80.8-
96.0%) within 48 months and 94.5% (95% CI:86.6-97.9%) within 60 months (Figure 4).  
 
Predictors of CRC at anastomotic location 
 Anastomotic CRC was significantly associated with the study size, so that larger studies 
yielded lower rate (OR, 0.98; 95% CI: 0.95-0.99; P=0.043). There was some evidence of an 
association between timing of the first colonoscopy and occurrence of anastomotic CRC (≥12 
months vs. <12 months, OR, 0.42; 95% CI: 0.15-1.13), although not reaching significance 
(p=0.089). (see Supplementary Table 2)  
 
Cancer at anastomotic location development according to cancer-site 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
We performed a subgroup analysis on the A-CRCs rates stratified according to the site of 
primary cancer (i.e., rectum vs. colon). Four studies16,23,24,33 provided data and were analyzed. 
Among primary rectal cancer group, 27 A-CRCs out of 482 primary rectal cancer were diagnosed 
during follow-up, yielding a pooled cumulative rate of 5.46% [95%CI 2.3-12.41]. Among primary 
colon cancer group, 18 A-CRCs out of 921 primary colon cancers were identified, yielding a pooled 
cumulative rate of 1.95% [95%CI 0.82-4.58]. Thus, patients with a history of rectal cancer 
compared to patients with prior colon cancer had a two-fold higher risk of developing an A-CRC 
during surveillance [Relative Risk 2.66; 95%CI 1.31-5.41]. 
 
Risk of bias 
Multivariate regression analysis indicated a significant negative association between the 
study sample size and occurrence of A-/NA-CRCs, suggesting that studies with limited sample 
sizes were more likely to report larger rates of A-/NA-CRCs. The negative correlation was not 
limited to a particular time-interval, thus possibly suggesting publication bias. We also evaluated 
publication bias by performing trim-and-fill procedure for each time-interval, separately.  
The number of studies was too small to test publication bias for time-intervals >120 months. 
Therefore, 11 trim-and-fill procedures were performed, of which only one yielded a A-/NA-CRCs 
rate (at the 6-12 months) potentially biased result because 7 studies could be missing. The 
imputation and inclusion of these studies, however, yielded a A-/NA-CRCs estimate (0.86%; 95% 
CI:0.40-1.00) comparable with the multivariate estimate (0.74%; 95% CI:0.50-1.09%). Thus, 
although it is likely there are unpublished studies not yet included, the impact attributable to 
publication bias is potentially minimal for this set of studies.  
According to the modified Newcastle-Ottawa scale for bias assessment, 17 out of 27 studies 
(63%) were judged at high risk of bias (see Supplementary Table 3 for details). 
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DISCUSSION 
After surgery for CRC, the highest risk of CRCs at anastomotic and non-anastomotic 
location was restricted to the early follow up period, with a decrease after 24-36 months from 
surgery and this time-dependent decrease was more evident for CRC at anastomotic than non-
anastomotic location.  
The clinical impact of the time-dependent incidence in the risk of NA-CRC is highly 
relevant because early diagnosis of NA-CRC is the main target of surveillance colonoscopy. 
According to our estimate, the absolute annual risk of NA-CRC is substantially lower than 1%, 
ranging between 0.63% and 0.74% in the first 3 years of follow up, further dropping to <0.5% after 
the 36 months. In addition, we excluded a peak of NA-CRC within the first year – i.e. 6-12 months 
– as the overall risk of NA-CRC appeared to be uniformly distributed in the first 36 months, the 
remaining being diluted in the next 13 years of follow up. This decrease of risk after 3 years from 
surgery is compatible with a missed lesion at pre-operative assessment rather than new-onset cancer 
due to an underlying high-risk status of the patient. In the latter case, indeed, a progressive increase 
of CRC risk at follow up should have been observed, similarly to that reported in long-lasting 
cohorts of ulcerative colitis or Lynch syndrome. Despite most of the included studies performed 
clearing colonoscopies at the CRC diagnosis, our findings confirm the need for a high-quality peri-
operative colonoscopy as recommended by current guidelines 38,39, before applying longer 
surveillance intervals. The finding that over 60% of NA-CRC were detected in stage I/II further 
supports the value of endoscopic surveillance, especially in the early high-risk period.   
In our review, we adopted the nomenclature of cancer at anastomotic and non-anastomotic 
location, that can reasonably be considered surrogates of recurrent and metachronous cancers, 
respectively. Cancers diagnosed during surveillance colonoscopy may also be named as post-
colonoscopy colorectal cancers (PCCRC). The World Endoscopy Organization 3 recently proposed 
an algorithm for the identification of the most plausible PCCRC explanation, considering five 
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groups (i.e., likely incomplete resection of previously identified lesion; detected lesion, not 
resected, possible missed lesion, prior examination adequate, possible missed lesion, prior 
examination negative but inadequate and likely new CRC). Unfortunately, in our study available 
data did not allow to categorize cancer as above suggested. However, early (<36 months) cancer at 
non-anastomotic location should very likely belong to the category “possible missed or 
incompletely resected lesion”. 
The absolute annual risk of A-CRC appeared to be >1% in each of the initial two years of 
follow up, dramatically decreasing to <0.5% after such period and disappearing after 60 months. Of 
note, 70% of the overall risk of A-CRC appeared to be restricted in the first 24 months of follow up. 
As focused only on mere detection of intraluminal A-CRC, our analysis would justify the role of an 
early endoscopy to rule out such occurrence. However, the clinical relevance of endoscopic 
detection of CRC at anastomotic location may be limited. Indeed, the clinical impact of early 
detection may be reduced by the co-existence of extra-mural disease, such as nodal or distant 
metastases. Extra-luminal peri-anastomotic recurrences are more frequent than luminal recurrences 
2,40,41
 and usually detected by computed tomography (CT) or CT-colonography 42,43. Once detected, 
patients are evaluated for further oncological treatments and generally quit colonoscopy 
surveillance.  Unfortunately, extra-luminal cancer rates were not reported in studies included in our 
review, likely due to a poor reporting quality. We showed a 2-fold higher rate of A-CRCs for rectal 
vs. colon location of the index tumour, although such information was provided only by 4 out of 27 
studies.  
While our data are informative for decision-making and clinical guidelines, there are 
limitations in our analysis. First, we did not incorporate the drop-out rate in our analysis, because it 
was provided by very few studies. However, it is unlikely that patients with A-/NA-CRCs would 
have not adhered to the planned study visit, so that the drop-out-related bias is more likely to over- 
rather than under-estimate the long-term risk. In addition, as most of the risk in our pooled cohort 
was in the very early phase of the follow up, the possible effect of drop-out rate may be 
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marginalized, especially when considering the very long CRC-survival associated with early stages 
that represented the vast majority of our population. Finally, the robustness of our results to the 
assumption that all initial CRCs (ie, CRCs included in the follow-up program) spanned the entire 
follow-up period, was confirmed by sensitivity analyses carried out for the studies reporting 
information on the number of patients actually present at each follow-up time interval (ie, patients 
at risk) (see supplementary appendix for details). Secondly, most studies were initiated before the 
advent of high-quality colonoscopy, so that there may be an overestimation of the post-surgery 
CRC risk. In addition, information of main key-quality indicators of colonoscopy, such as caecal 
intubation and level of cleansing were not available for most of the studies. Indeed, only 3 out of 27 
studies clearly specified that surveillance colonoscopy was high-quality colonoscopy or assessed 
the quality of colonoscopy, thus precluding any analysis. It is very likely that this is due to poor 
reporting, especially for the most recent series, while this could be an issue for the oldest series. 
Notably, the year of ending the enrollment (<2005 vs ≥2005) was not a predictor of developing 
CRCs at the metaregression analysis. Quality of colonoscopy is more than achieving the caecum or 
ileo-colonic anastomosis and adequate bowel preparation; however, more recent key-quality 
indicators, such as the importance of the adenoma detection rate and withdrawal time, the need for 
continuous re-training and internal audit to maintain high quality standard were not considered in 
studies included in our systematic review. Indeed, also in the few studies clearly stating that “high-
quality” colonoscopy was performed a non-negligible rate of NA-CRCs was attributable to missed 
lesions. In the study by le Clercq et al 36, about 40% of NA-CRCs were due to missed lesions during 
surveillance. Nevertheless, in the study by Marques-Antunes et al 37, patients that underwent a high-
quality baseline colonoscopy presented a significantly lower risk of having advanced adenomas at 
surveillance, thus underscoring the importance of quality of colonoscopy at baseline and 
surveillance investigation to reduce the incidence of CRCs. However, as already outlined, the 
decrease in the risk of NA-CRC after the third year from surgery is reassuring regarding the use of 
longer surveillance colonoscopy intervals after the early period. Third, the pooling of incidence data 
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at each specific time-point differed among the studies leading to multiple combined cohorts at 
different time-points. However, the temporal trends in both A/NA-CRCs were so clear as to 
indicate an internal robustness in our analysis. In addition, we did not find differences according to 
whether US recommendations on surveillance (i.e., 1-3-5-year protocol) were followed. Fourth, we 
limited our analysis of endoscopic surveillance to cancer detection, despite endoscopic surveillance 
may be effective also as preventive technique by removing precancerous lesions. However, there is 
a clear hierarchy in outcomes between cancer detection and prevention, so that the main goal of 
early post-surgery surveillance is represented by the detection of malignancies.  
Finally, older studies may be more prone to poor reporting. The choice of beginning the 
literature search from 1985 may be questioned, however this allowed us to have consistent data and 
evaluate possible changes of cancer detection over time. Indeed, the analyses were based on 27 
studies performed throughout a 30-year period. Notably, poor reporting was unfortunately a 
constant independently of the year of publication. Lack of information such as quality of 
colonoscopy, drop-out rates and incidence of extra-luminal recurrences strongly limited the quality 
of the available evidences. Despite most of the included studies were scored at high-risk of bias, 
this could have been overestimated due to poor reporting. Indeed, items with missing information 
were considered at substantial risk of bias. 
Large, prospective, multicenter, international studies should be performed in order to verify 
the impact of high-quality peri-operative colonoscopy on the risk of A-/NA-CRCs and to identify 
subgroups of patients at higher risk, thus enabling tailored endoscopic surveillance.  
In conclusion, the present systematic review further strengthens the current guidelines 
recommendations 2,42,43.  We showed a concentration of the post-surgery CRCs at surveillance 
colonoscopy in the very early phase of follow up, with a decrease thereafter. The present systematic 
review confirms the need for an as early as 1-year and 3-year surveillance colonoscopy. When 
considering the significant drop of the incidence after such period, longer surveillance intervals (i.e. 
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5-year) are reasonable. Challenge of the future is the assessment of the impact of high-quality 
colonoscopy on the early diagnosis and prevention of post-surgery CRCs.  
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Figure legend 
Figure 1. Non-anastomotic CRCs rate plotted against the time intervals from <12 months to ≥180 
months after the initial CRC resection. 
Figure 2. Cumulative proportion of non-anastomotic CRCs on all non-anastomotic CRCs, at 
various time-intervals. 
Figure 3. Anastomotic CRCs rates plotted against the time follow-up intervals from <12 months to 
≥180 months after the initial CRC resection. 
Figure 4. Cumulative proportion of anastomotic CRCs on all anastomotic C Cs, at various time-
intervals. 
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Table legend 
Table 1. Baseline characteristics of the included studies 
Table 2. Characteristics of index colorectal cancer (CRC) cases 
Table 3. Colorectal cancer (CRC) diagnosed during follow-up. 
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Table 1 – Baseline characteristics of the included studies. RCT: randomized controlled trial; NA: Not Available; 
*High quality colonoscopy means scope introduction up to the caecum or ileo-colonic anastomosis with adequate bowel preparation 
Reference Enrolment period Study Design Study location n centers n CRC n patients Mean age (years) 
Male gender 
(%) 
Quality* of 
colonoscopy Risk of bias 
Weber et al, 1986 11 1978-1986 Retrospective USA 1 79 75 71 NA NA High 
Michael et al, 1988 12 1983-1988 Retrospective UK 1 63 63 NA NA NA High 
Brady et al, 1990 13 NA Prospective USA 1 207 207 NA NA NA High 
Himal et al, 1991 14 1982-NA Retrospective Canada 1 112 112 NA NA NA High 
McFarland et al, 1991 15 1980-NA Prospective UK 1 74 74 66 50 NA High 
Granqvist et al, 1992 16 1981-1990 Retrospective Sweden 1 396 390 64 47.4 NA High 
Patchett et al, 1993 17 1983-NA Prospective UK 1 132 132 63.5 59.1 NA Intermediate 
Chen et al, 1994 18 1972-1990 Prospective Australia 1 231 231 NA 48.5 NA Intermediate 
Khoury et al, 1996 19 1984-1994 Retrospective USA 1 389 389 65.8 53.2 NA High 
Leggett et al, 1997 20 1980-NA Retrospective Australia 1 433 433 NA NA NA High 
Barrier et al, 1998 21 1986-NA Retrospective France 1 179 175 66 55.4 High Intermediate 
Togashi et al, 1999 22 1992-1995 Retrospective Japan 1 341 341 59.6 61.3 NA Intermediate 
Stigliano et al, 2000 23 1970-1988 Retrospective Italy 1 322 322 NA NA NA Intermediate 
McFall et al, 2003 24 1990-2002 Retrospective UK 1 226 226 67.7 46 NA High 
Skaife et al, 2003 25 NA Prospective Singapore 1 611 611 66.7 53.2 NA High 
Ntinas et al, 2004 26 2001-2004 Retrospective Greece 1 41 41 69.5 65.9 NA High 
Lan et al, 2005 27 1981-2001 Retrospective Taiwan 1 3846 3846 63.9 70.9 NA Intermediate 
Mathew et al, 2006 28 1998-2003 Retrospective UK 1 105 105 67.8 58.1 NA High 
Hassan et al, 2006 29 1998-2004 Prospective Italy 3 318 318 62 51.6 NA High 
Ballesté et al, 2007 30 2000-2001 Prospective Spain 10 355 355 67 62.8 NA High 
Wang et al, 2009 (intensive surveillance) 31 1995-2001 RCT -Prospective China 1 165 165 54.6 53.5 NA Low 
Wang et al, 2009 (routine surveillance) 31 1995-2001 RCT- Prospective China 1 161 161 54.4 55.3 NA Low 
Hahn et al, 2012 32 2001-2009 Prospective Korea 1 58 58 62.7 53.5 NA High 
Sakamoto et al, 2013 33 2004-2005 Retrospective Japan 1 459 459 62 58.4 NA Intermediate 
Heo et al, 2014 34 2005-2010 Retrospective Korea 1 70 70 63.2 52.9 NA High 
Battersby et al, 2014 35 1995-2012 Prospective UK 1 538 538 70.8 56.3 NA High 
le Clercq et al, 2015 36 2001-2010 Retrospective Netherlands 3 5357 5157 70 53.7 High Low 
Marques-Antunes et al, 2017 37 2008-2011 Retrospective Portugal 1 535 535 65 62.2 High Intermediate 
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Table 2. Characteristics of index colorectal cancer (CRC) cases 
Reference Number of patients 
Number 
of CRC 
Number of  index 
CRC cases located 
in the colon 
Number of  index 
CRC cases located 
in the rectum 
Number of 
patients with 
index CRC 
cases located 
in the colon 
Number of 
patients with 
index CRC 
cases located 
in the rectum 
Site of index 
Colon 
Cancer: 
proximal to 
splenic 
flexure (N) 
Index 
CRC 
stage I 
Index 
CRC 
stage II 
Index 
CRC 
stage III 
Index CRC 
stage IV 
Weber et al, 1986 11 75 79 58 21 54 21 22 13 44 15 3 
Michael et al, 1988 12 63 63 NA NA NA NA NA NA NA NA NA 
Brady et al, 1990 13 207 207 207 0 207 0 NA NA NA NA NA 
Himal et al, 1991 14 112 112 NA NA NA NA NA NA NA NA NA 
McFarland et al, 1991 15 74 74 48 26 48 26 19 11 35 25 NA 
Granqvist et al, 1992 16 390 396 302 94 296 94 176 59 187 108 36 
Patchett et al, 1993 17 132 132 NA NA NA NA NA 23 72 37 NA 
Chen et al, 1994 18 231 231 NA NA NA NA NA NA NA NA NA 
Khoury et al, 1996 19 389 389 284 105 284 105 149 136 148 93 12 
Leggett et al, 1997 20 433 433 NA NA NA NA NA NA NA NA NA 
Barrier et al, 1998 21 175 179 134 45 130 45 54 13 111 55 NA 
Togashi et al, 1999 22 341 341 190 151 190 151 63 NA NA NA NA 
Stigliano et al, 2000 23 322 322 182 140 182 140 38 67 189 66 NA 
McFall et al, 2003 24 226 226 127 99 127 99 69 50 112 64 NA 
Skaife et al, 2003 25 611 611 NA NA NA NA NA NA NA NA NA 
Ntinas et al, 2004 26 41 41 NA NA NA NA NA 1 18 23 7 
Lan et al, 2005 27 3846 3846 NA NA 1895 1951 NA 845 1609 1388 NA 
Mathew et al, 2006 28 105 105 NA NA NA NA NA 19 54 26 NA 
Hassan et al, 2006 29 318 318 NA NA NA NA NA 265 48 5 0 
Ballesté et al, 2007 30 355 355 NA NA NA NA 83 75 158 116 6 
Wang et al, 2009 (intensive 
surveillance) 31 
165 165 88 77 88 77 NA 48 67 50 NA 
Wang et al, 2009 (routine 
surveillance) 31 
161 161 83 78 83 78 NA 52 66 43 NA 
Hahn et al, 2012 32 58 58 58 0 58 0 44     
Sakamoto et al, 2013 33 459 459 310 149 310 149 NA NA NA 174 0 
Heo et al, 2014 34 70 70 35 35 35 35 17 NA NA NA NA 
Battersby et al, 2014 35 538 538 295 246 295 246 174 106 225 214 8 
le Clercq et al, 2015 36 5157 5357 NA NA NA NA NA 1126 1482 1280 1340 
Marques-Antunes et al, 
2017 37 
535 535 535 0 535 0 100 107 180 221 23 
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Table 3. Colorectal cancer (CRC) diagnosed during follow-up. CS, colonoscopy; NA, not available.  
Reference Follow-up protocol 
Mean 
follow-up 
(months) 
Clearing 
colonoscopy 
performed 
Anastomotic and 
Non-Anastomotic 
CRCs 
Non-
Anastomotic 
CRCs 
Anastomotic 
CRCs 
Weber et al, 1986 11 CS preoperatively when possible and postoperatively at regular intervals (semiannually for the first 2 years and annually thereafter) 33.6 Yes 3 3 0 
Michael et al, 1988 12 CS at 3, 9, 15 and 21 months after resection (not carried in all pts) NA Yes 2 2 0 
Brady et al, 1990 13 CS annually or at 2-year intervals after the first 2 examinations, 
conducted for 2 to 8 years NA NA 15 9 6 
Himal et al, 1991 14 CS every 3 months in the 1st year and every 6 months in the 2nd and 3rd year NA Yes 17 0 17 
McFarland et al, 1991 15 CS yearly for first 5 years, then 2 yearly 51.6 NA 2 0 2 
Granqvist et al, 1992 16 CS at 6 months or preoperatively, then two years later, and then every fourth year until the age of about 70 years NA Yes 26 12 14 
Patchett et al, 1993 17 CS after operation and at 6, 12, 18, 30 and 48 months 66 Yes 8 2 6 
Chen et al, 1994 18 CS at 1st and 3rd year post-operatively 67 NA 4 4 0 
Khoury et al, 1996 19 Clearing CS peri-operatively, then first surveillance CS within the first 24 months postoperatively NA Yes 3 1 2 
Leggett et al, 1997 20 CS at 6 months and at three-year intervals thereafter; if 2 or more polyps 
were found, CS was performed at intervals of 18 months 45 Yes 21 10 11 
Barrier et al, 1998 21 CS at 12 months, 30 months, 54 months after operation NA 
Clearing CS 
performed in 
61/175 patients 
14 3 11 
Togashi et al, 1999 22 Pre-operative CS and then CS at least twice during a period of ≥ 3 years 
after surgery. 72 Yes 22 22 0 
Stigliano et al, 2000 23 Clean CS before surgery, then CS once yearly for the first 5 years and then every 2 years 105 Yes 27 5 22 
McFall et al, 2003 24 
The frequency of colonoscopic surveillance amongst those screened was 
not determined by a rigid protocol (many factors were considered to 
decide interval between repeat CS) 
NA NA 15 9 6 
Skaife et al, 2003 25 Colonoscopy routinely scheduled annually for all patients until the colon 
was polyp-free, then three to five yearly thereafter 44 Yes 9 5 4 
Ntinas et al, 2004 26 CS at 6 months, at 12 months then annually NA Yes 2 0 2 
Lan et al, 2005 27 First CS at 6 months after surgery or 1 year; if negative, 2 or 3 years later; if negative, 5 years later; if a CS is positive, next is at 1 year 72 Yes 43 43 NA 
Mathew et al, 2006 28 2 and 5-year scheduled CS NA NA 5 2 3 
Hassan et al, 2006 29 CS at 1-year, 3-year and 5-year NA Yes 10 10 0 
Balleste' et al, 2007 30 CS performed between the 1st and 2nd year after surgery 18 NA 14 7 7 
Wang et al, 2009  
(intensive surveillance) 31 
Colonoscopy every 3 months for the first year, every 6 months for the 
next 2 years and then annually for the next 2 years 
74 months 
for 161 
patients 
Yes 13 3 10 
Wang et al, 2009  
(routine surveillance) 31 
Colonoscopy at 6, 30, and 60 months postoperatively (not necessary at 6 
months if it had been performed preoperatively) 
69 months 
for 158 Yes 18 6 12 
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Hahn et al, 2012 32 CS annually 41 Yes 0 0 0 
Sakamoto et al, 2013 33 Pre-operative CS and post-operative CS not schematically defined 60 Yes 9 6 3 
Heo et al, 2014 34 CS performed at 6 months, then annually or biennially after the initial treatment NA Yes 1 1 0 
Battersby et al, 2014 35 CS at 1-year, 3-year and 5-year 50 Yes 15 15 NA 
le Clercq et al, 2015 36 
Clearing CS pre-operatively or within 3 months post-operatively, 
followed by a CS at 3 years. Subsequent CS was at 6y when 1-2 
adenomas were found, at 3y when 3 or more adenomas were found 
NA Yes 98 98 NA 
Marques-Antunes et al, 2017 37 Not defined in the article. Directly asked to the Authors: CS at 1-year, 3-year and 5-year 62 Yes 38 18 20 
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After surgery for colorectal cancer (CRC), a significant decrease after 24-36 months of the incidence 
of cancer at anastomotic (A) and non-anastomotic (NA) location was detected. 
The time-dependent decrease was more evident for cancer at anastomotic location. 
Highest risk of CRCs at anastomotic and non-anastomotic location in the first 24-36 months
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SUPPLEMENTAL MATERIAL 
Supplementary Appendix containing: Results for the separate univariate random effects meta-
analysis (Independent random effects meta-analyses). Results from the multivariate random-
effect meta-analysis. Table A1 - Meta-analysis results for the independent random-effects model 
and the models 1 and 2 from multivariate approach for the rate of NA-CRCs at different follow-
up time points. The issue of missing information (dropouts/deaths). 
 
Supplementary Figure 1. Study flow-chart. 
 
Supplementary Table 1. Multivariate meta-analysis via random-effects regression model 
assessing predictors of occurrence of non-anastomotic CRC over time. The regression analysis 
was performed by adding study-level factors (such as gender) to the model involving the time as 
predictor of effects. Two-way interactions for all considered variables were not significant and 
therefore not included in the final model. 
 
Supplementary Table 2. Multivariate meta-analysis via random-effects regression model 
assessing predictors of anastomotic CRCs over time. The regression analysis was performed by 
adding study-level factors (such as gender) to the model involving the time as predictor of 
effects. Two-way interactions for all considered variables were not significant and therefore not 
included in the final model. 
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Supplementary Table 3. Assessment of risk of bias for included studies according to modified 
Newcastle-Ottawa Scale. Green “*” denotes low risk of bias, red “-“ indicates substantial risk of 
bias. 
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Supplementary Appendix 
Results for the separate univariate random effects meta-analysis (Independent random effects 
meta-analyses) 
We first ran separate univariate random effects meta-analyses for each time point of interest. The results 
in Table A1 clearly shows that the odds of NA-CRC were significantly higher in the first 36 months after 
primary CRC resection. In details, the NA-CRC rate was 0.59 (0.36;0.97) at 6-12 months, which did not 
decreased significantly  at 13-24 months (OR, 0.78; 95% CI0.42-1.61; P=0.251 and at 25-36 months (OR, 
0.89; 95% CI:0.54-1.98; P=0.571). Time points >36 months provided significantly different estimates. At 
37-48 months a significant decrease in NA-CRC rate (as compared with 6-12 months) was observed (OR, 
0.58; 95% CI:0.26-0.96;P=0.026). 9%). This was consistent across longitudinal time points >36 months.   
 
Results from the multivariate random-effect meta-analysis  
Table A1 shows the results of applying the multivariate random-effects meta-analysis mixed model to the 
data using two different models:  
1. Random study effects, model 1 -  “CS” compound symmetry structure;  This model accounts 
for dependence between outcomes by assigning a random intercept effect that is common to all 
longitudinal effect sizes from a given study while assuming zero within-study serial correlations 
between longitudinal effect sizes.  By including a random study effect, we automatically induce a 
correlation between any two effect sizes within a study. These correlations are assumed to be the 
same for each set of time points, regardless of the time lag between the time points. This 
covariance structure is also known as compound symmetry. However, this model allows only one 
random effect for all the longitudinal effect sizes from each study and therefore ignores the serial 
correlation between effect sizes for instance, effect sizes closer together tend to be more strongly 
correlated than those measured far apart due to factors such as characteristics of patients at longer 
follow-up.  
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2. Correlated random study effects,  model 2-  for a “AR” structure. This is an extension of the 
independent random time effects model where the dependence between effect sizes is accounted 
for through the dependence between random time effects. This model imposes heteroscedastic 
AR  covariance structure for the random time effects while assuming zero within-study serial 
correlations between longitudinal effect sizes. Therefore, the dependence between effect sizes 
become stronger as the lag between them gets smaller. This is plausible in longitudinal studies 
where loss-to-follow up increases with time such that effect sizes measured far apart have less 
dependence than those closer to one another. 
 
The results of applying the multivariate random-effects model to the data using models 1 and 2 are shown 
in Table A1. Inspection of the estimates from all the three models show slight differences between the 
models. It’s also clear that the pattern of the results was the same across all the 3 models: the odds of NA-
CRC at time points >36 months after resection were lower as compared with those at the first 36 months. 
The model fit as shown by the values of Akaike Information Criterion (AIC), where smaller values 
indicate better fit, show that  models 1 and 2 had better fit than the independence model. The model that 
performed best was the AR model using the heteroscedastic autoregressive structure. Therefore, in the 
manuscript we reported results from this model.  
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Table A1 - Meta-analysis results for the independent random-effects model and the models 1 and 2 
from multivariate approach for the rate of NA-CRCs at different follow-up time points.  
 Indep random effects Random effects Model 1 - "CS" Random effects Model 2 - "AR" 
Time 
Rate 
[95% CI] 
ORs 
[95% CI] P 
Rate 
[95% CI] 
ORs 
[95% CI] P 
Rate 
[95% CI] 
ORs 
[95% CI] P 
6-12 
0.59 
(0.36;0.97) - - 
0.79 
(0.55;1.15) - - 
0.74 
(0.50;1.09) - - 
13-24 
0.49 
(0.32;0.77) 
0.83 
(0.42;1.61) 0.575 
0.62 
(0.43;0.9) 
0.78 
(0.51;1.19) 0.251 
0.63 
(0.47;0.90) 
0.81 
(0.53;1.25) 0.349 
25-36 
0.61 
(0.4;0.93) 
1.03 
(0.54;1.96) 0.933 
0.70 
(0.48;1.02) 
0.89 
(0.58;1.35) 0.571 
0.69 
(0.49;1.01) 
0.94 
(0.62;1.46) 0.778 
37-48 
0.3 
(0.2;0.46) 
0.50 
(0.26;0.96) 0.038 
0.47 
(0.3;0.71) 
0.58 
(0.36;0.94) 0.026 
0.45 
(0.29;0.7) 
0.61 
(0.37;0.98) 0.031 
49-60 
0.26 
(0.17;0.38) 
0.43 
(0.23;0.81) 0.008 
0.37 
(0.24;0.58) 
0.47 
(0.29;0.76) 0.002 
0.34 
(0.24;0.58) 
0.48 
(0.29;0.81) 0.005 
61-72 
0.35 
(0.23;0.55) 
0.60 
(0.31;1.15) 0.122 
0.53 
(0.33;0.84) 
0.66 
(0.4;1.1) 0.109 
0.54 
(0.33;0.88) 
0.73 
(0.42;1.26) 0.256 
73-84 
0.17 
(0.11;0.27) 
0.29 
(0.15;0.56) <0.001 
0.33 
(0.19;0.57) 
0.42 
(0.23;0.74) 0.003 
0.34 
(0.19;0.6) 
0.46 
(0.25;0.85) 0.014 
85-96 
0.24 
(0.1;0.57) 
0.40 
(0.15;1.1) 0.076 
0.29 
(0.14;0.56) 
0.36 
(0.18;0.72) 0.004 
0.29 
(0.15;0.56) 
0.41 
(0.19;0.84) 0.016 
97-108 
0.21 
(0.09;0.52) 
0.35 
(0.13;0.99) 0.049 
0.3 
(0.16;0.57) 
0.37 
(0.19;0.74) 0.005 
0.3 
(0.15;0.58) 
0.4 
(0.19;0.83) 0.013 
109-120 
0.21 
(0.08;0.53) 
0.35 
(0.12;1.01) 0.053 
0.27 
(0.14;0.52) 
0.34 
(0.17;0.68) 0.002 
0.28 
(0.14;0.57) 
0.38 
(0.18;0.81) 0.011 
121-132 
0.13 
(0.05;0.34) 
0.22 
(0.08;0.64) 0.005 
0.18 
(0.07;0.43) 
0.22 
(0.09;0.55) 0.001 
0.18 
(0.07;0.45) 
0.24 
(0.09;0.63) 0.003 
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133-144 
0.14 
(0.07;0.29) 
0.24 
(0.1;0.57) 0.001 
0.23 
(0.12;0.44) 
0.28 
(0.14;0.57) <0.001 
0.24 
(0.12;0.48) 
0.32 
(0.15;0.68) 0.003 
145-156 
0.15 
(0.06;0.41) 
0.26 
(0.09;0.78) 0.016 
0.18 
(0.06;0.49) 
0.22 
(0.08;0.63) 0.005 
0.17 
(0.06;0.47) 
0.22 
(0.08;0.66) 0.007 
157-168 
0.1 
(0.04;0.22) 
0.16 
(0.06;0.42) <0.001 
0.14 
(0.06;0.34) 
0.17 
(0.07;0.43) <0.001 
0.14 
(0.06;0.36) 
0.19 
(0.07;0.51) 0.001 
169-180 
0.15 
(0.06;0.39) 
0.26 
(0.09;0.74) 0.012 
0.24 
(0.11;0.53) 
0.3 
(0.13;0.68) 0.004 
0.22 
(0.09;0.51) 
0.29 
(0.12;0.72) 0.007 
AIC 597.76   531.13   529.93   
l ogLik -266.8818   -247.5686   -246.9698   
Indep = Independence       
CS = Compound symmetry       
AR = autoregressive structure       
AIC = Akaike information criterion (AIC)       
LogLik= log-likelihood       
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The issue of missing information (dropouts/deaths).  
As already discussed in the manuscript, the majority of the included studies provided incomplete 
information because of missing data due to dropouts and/or deaths. A few studies provided information 
about patients who were actually present at each time interval, but they did not distinguish between 
censoring by dropout and deaths. Therefore, the two patterns of deaths vs. dropouts could not be 
separated. To assess the robustness of our results to the assumption that all initial CRCs (i.e. CRCs 
included in the follow-up program) spanned the entire follow-up period, sensitivity analyses were carried 
out for the studies (15 trials of 8911 patients) reporting information on the number of patients being alive 
and being not censored (i.e., patients at risk) at each follow-up time interval.  
 
In Figure A, the mean and 95% CIs of the proportion of patients being alive and being not censored per 
time-point are presented. Within 48 months, the means proportions remained rather constant, and they 
were very high (range, 99%-96%). There was a decrease in the observed means for follow-up time >48 
months: at 49-60 months, the mean proportion of patients at risk was 91.0% and decreased not 
significantly to 90% at 97-108 months. Concerning statistical analyses on the level of time-points, two 
approaches for dealing with missing data were used: 1. omitting all studies with missing information and 
analyzing them as a separate group; 2. using an imputation method for missing information that retain all 
the data.  
 
Approach 1- Restricting the analysis to the subgroup of studies reporting the number of patients at risk, 
we found that 1) NA-CRCs occurred in 0.84% (95% CI:0.48-1.50%) between 6 and 12 months, in 0.80% 
(95% CI:0.44-1.44%) between 13 and 24 months and in 1.00% (95% CI:0.57-1.23%) between 25 and 36 
months. Differences in time points were not statistically significant. Over the longer times, rate of NA-
CRC decreased (significantly) to 0.50% (95% CI:0.25-1.00%; P=0.045) between 37 and 48 months and to 
0.47% (95% CI:0.20-0.68%; P=0.007) between 73 and 84 months. Note, the results from this sub-analysis 
are consistent with those from the simplest model ignoring dropout/deaths (Table A1).  
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Approach 2 - We assumed that the studies reporting information on the number of patient at risk at 
different time points were similar to those with missing information. Then, in the complete dataset, 
denominators with missing information were adjusted based on the expected distribution of dropout/death 
rate (shown in Figure A). In table A2, the model assuming dropout/death is presented together with the 
simplest model ignoring dropout/death. The results from the model assuming dropout/deaths were 
statistically comparable to those from the simplest model where dropout (death and censoring) was not 
taken into account. The pattern of the two models was also the same: the odds of NA-CRCs at time >36 
months were lower than were those within 36 months: 37-48 months vs. 6-12 months, ORs, 0.62; 95% 
CI:0.52-1.13; P=0.050; 48-60 months vs. 6-12 months, OR, 0.40; 95% CI:0.25 0.62; P=0.011). Therefore, 
we think that the simplest model assuming no dropout/deaths satisfies all criteria for responding to the 
study questions.  
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Figure A - Means and 95% CIs of the proportion of patients at risk for different follow-up times.  
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table A2 - Estimates of NA-CRCs times starting from the model for the hypothetical cohort without 
dropout/deaths. Dropout/death rates for all times points were extracted from the subgroup of the studies 
reporting information on the patients who were complaints at follow-up times .  
Time 
Model assuming 
no dropout/deaths 
% of 
patients at 
risk 
Dropout/Death 
Rate 
Model 
assuming 
dropout/deaths 
6-12 0.74 (0.51;1.10) 0.989 0.011 0.76 (0.51-1.11) 
13-24 0.63 (0.47;0.90) 0.974 0.026 0.62 (0.43-0.91) 
25-36 0.69 (0.49;1.01) 0.967 0.033 0.72 (0.49-1.06) 
37-48 0.45 (0.29;0.70) 0.956 0.044 0.47 (0.30-0.73) 
48-60 0.34 (0.24;0.58) 0.913 0.087 0.40 (0.25-0.62) 
61-72 0.54 (0.33;0.88) 0.966 0.034 0.57 (0.35-0.92) 
73-84 0.34 (0.19;0.6) 0.925 0.075 0.37 (0.21-0.65) 
85-96 0.3 (0.15;0.6) 0.901 0.099 0.33 (0.21-0.66) 
97-108 0.3 (0.15;0.58) 0.901 0.099 0.33 (0.17-0.67) 
109-120 0.28 (0.14;0.57) 0.806 0.194 0.35 (0.18-0.70) 
121-132 0.18 (0.07;0.45) 0.806 0.194 0.23 (0.09-0.57) 
133-144 0.24 (0.12;0.48) 0.629 0.371 0.38 (0.19-0.76) 
145-162 0.17 (0.06;0.47) 0.629 0.371 0.27 (0.10-0.77) 
163-174 0.14 (0.06;0.36) 0.479 0.521 0.29 (0.12-0.72) 
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 Literature	  search 
Period:	  through	  January	  1st,	  2018.	   
Databases:	  PubMed,	  EMBASE,	  Scopus,	  Scholar,	   
Cochrane	  Central	  Register	  of	  Clinical	  Trials. 
Publication:	  Full	  text	  only. 
Language:	  English	  language	  only. 
Design:	  Prospective	  and	  retrospective	  surveillance	  studies. 
 
Screening 
Included 
Eligibility 
Identification 
2373	  studies	  were	  identified	  from	  databases 
2095	  studies	  were	  excluded	  by	  titles 
Irrelevant:	  1708 
Reviews:	  387 
278	  studies	  were	  retrieved	  for	  more	  details	  	  
and	  application	  of	  inclusion	  criteria 
241	  studies	  were	  excluded 
f-­‐u	  method	  not	  explicitly	  reported:	  97 
time	  of	  cancer	  detection	  not	  reported:	  60 
cancer	  outcome	  not	  evaluated:	  35 
survey:	  29 
editorial	  or	  review	  article:	  16 
endoscopic	  protocol	  not	  specified:	  14 
27	  studies	  included 
15,589	  patients 
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Supplementary Table 1. Multivariate meta-analysis via random-effects regression model assessing 
predictors of occurrence of non-anastomotic CRC over time. The regression analysis was performed by 
adding study-level factors (such as gender) to the model involving the time as predictor of effects. Two-way 
interactions for all considered variables were not significant and therefore not included in the final model. 
 
Variable ORs [95% CI] P value 
Time interval (months)   
6-12 - - 
13-24 0.81 (0.53;1.26) 0.349 
25-36 0.94 (0.62;1.46) 0.778 
37-48 0.61 (0.37;0.98) 0.031 
49-60 0.48 (0.29;0.81) 0.005 
61-72 0.73 (0.42;1.26) 0.256 
73-84 0.46 (0.25;0.85) 0.014 
85-96 0.4 (0.19;0.84) 0.016 
97-108 0.4 (0.19;0.83) 0.013 
109-120 0.38 (0.18;0.81) 0.011 
121-132 0.24 (0.09;0.63) 0.003 
133-144 0.32 (0.15;0.68) 0.003 
145-156 0.22 (0.08;0.66) 0.007 
157-168 0.19 (0.07;0.51) 0.001 
169-180 0.29 (0.12;0.72) 0.007 
Mean patient age (as a continuous variable) 0.95 (0.88-1.03) 0.205 
Gender (M > 50% vs. M < 50%) 1.01 (0.44-2.34) 0.977 
Primary CRC site (colon vs. rectum) 0.98 (0.17-5.71) 0.985 
1-3-5-year endoscopic surveillance protocol 
implementation 
0.72 (0.41-1.28) 0.267 
Date of enrollment ending  
(≥ 2005 vs. < 2005) 
1.56 (0.61-3.97) 0.356 
Study size 0.96 (0.95-0.98) <0.001 
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Supplementary Table 2. Multivariate meta-analysis via random-effects regression model assessing 
predictors of anastomotic CRCs over time. The regression analysis was performed by adding study-level 
factors (such as gender) to the model involving the time as predictor of effects. Two-way interactions for all 
considered variables were not significant and therefore not included in the final model. 
 
Variable ORs [95% CI] P value 
Time interval (months)   
6-12 - - 
13-24 0.72 (0.44-1.24)  0.219 
25-36 0.56 (0.32-0.98) 0.036 
37-48 0.18 (0.08-0.39) 0.001 
49-60 0.21 (0.18;0.38) <0.001 
61-72 0.18 (0.09-0.41) <0.001 
73-84 0.19 (0.06-0.51) 0.001 
85-96 0.19 (0.09-0.65) 0.001 
97-108 0.18 (0.05-0.71) 0.012 
109-120 0.23 (0.05;1.01) 0.048 
121-132 0.23 (0.05;1.01) 0.048 
133-144 0.23 (0.05;1.01) 0.048 
145-156 0.23 (0.05;1.01) 0.048 
157-168 0.23 (0.05;1.01) 0.048 
169-180 0.23 (0.05;1.23) 0.090 
Timing of the 1st surveillance colonoscopy  
(≥12 months vs. <12 months) 
0.42 (0.15-1.13) 0.089 
Mean patient age 0.99 (0.85-1.16) 0.929 
Gender (M > 50% vs. M < 50%) 1.86 (0.41-8.57) 0.424 
Primary CRC site (colon vs. rectum) 0.99 (0.99-1.01) 0.198 
1-3-5 years endoscopic surveillance protocol 
implementation 
0.42 (0.15-1.13) 0.182 
Date of enrollment ending  
(≥ 2005 vs. < 2005) 
1.11(0.30-4.13) 0.871 
Study size 0.98 (0.95-0.99) 0.043 
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Supplementary table 3. Assessment of risk of bias for included studies according to modified 
Newcastle-Ottawa Scale. Green “*” denotes low risk of bias, red “-“ indicates substantial risk of 
bias. Those studies in which the mean follow-up length was reported and it was at least 60 months 
after resection (i.e., thus allowing two surveillance colonoscopies to be performed), were 
considered at low-risk of bias.  
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Weber et al, 1986 11 * * - - 2 High 
Michael et al, 1988 12 * * - - 2 High 
Brady et al, 1990 13 * * - - 2 High 
Himal et al, 1991 14 * * - - 2 High 
McFarland et al, 1991 15 * * - - 2 High 
Granqvist et al, 1992 16 * - - - 1 High 
Patchett et al, 1993 17 * * * - 3 Intermediate 
Chen et al, 1994 18 * * * - 3 Intermediate 
Khoury et al, 1996 19 * * - - 2 High 
Leggett et al, 1997 20 * * - - 2 High 
Barrier et al, 1998 21 * * - * 3 Intermediate 
Togashi et al, 1999 22 * * * - 3 Intermediate 
Stigliano et al, 2000 23 * * * - 3 Intermediate 
McFall et al, 2003 24 * * - - 2 High 
Skaife et al, 2003 25 * * - - 2 High 
Ntinas et al, 2004 26 * * - - 2 High 
Lan et al, 2005 27 * * * - 3 Intermediate 
Mathew et al, 2006 28 * * - - 2 High 
Hassan et al, 2006 29 * * - - 2 High 
Balleste' et al, 2007 30 * * - - 2 High 
Wang et al, 2009 (intensive surveillance) 31 * * * * 4 Low 
Wang et al, 2009 (routine surveillance) 31 * * * * 4 Low 
Hahn et al, 2012 32 * * - - 2 High 
Sakamoto et al, 2013 33 * * * - 3 Intermediate 
Heo et al, 2014 34 * * - - 2 High 
Battersby et al, 2014 35 * * - - 2 High 
le Clercq et al, 2015 36 * * * * 4 Low 
Marques-Antunes et al, 2017 37 * * * - 3 Intermediate 
 
